Metrics as of 10/15/2026, 11:33 AM (Berlin time), refresh in progress.
Cullinan Therapeutics Stock
Cullinan Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Nadim Ahmed
- Employees
- 109
- Market cap
- $795 M
- IPO
- 08/01/2021
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T…
Cullinan Therapeutics stock: price history
1D
-7.6%
1W
-16.7%
1M
-37.3%
6M
-14.1%
YTD
+24.9%
1Y
+47.9%
2Y
-26.6%
5Y
-48.3%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~14% stronger price swings than usual
Cullinan Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies to treat cancer and autoimmune diseases. Its portfolio comprises various drug candidates including bispecific T-cell engagers and an EGFR inhibitor, which are in clinical phases 1 or 2b. The company leverages strategic partnerships with partners such as Taiho Pharmaceutical Co., Ltd and Adimab, LLC as well as licensing agreements to commercialize its products for research and development purposes.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Cullinan Therapeutics
Analyst assessment of Cullinan Therapeutics
PRICE TARGET LOW
US$27.00
CONSENSUS
US$34.75
MEDIAN
US$36.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 02/10/2026
Cullinan Therapeutics stock metrics
P/E
-3.84
P/B
2.47
EV/EBITDA
-3.65
RETURN ON EQUITY
-16.7%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
78.2%
FLOAT SHARES
48,086,471
AVG. DAILY VOLUME (30D)
1,190,330
Insider transactions (SEC)
Michaelson Jennifer
Michaelson Jennifer
Michaelson Jennifer
Michaelson Jennifer
Michaelson Jennifer
Institutional holders
Comparable stocks
Frequently asked questions about Cullinan Therapeutics stock
What does Cullinan Therapeutics do?
Cullinan Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Nadim Ahmed, the company employs around 109 people.
The IPO was on 08/01/2021; the stock trades on NASDAQ under the ticker CGEM.
What do analysts say about Cullinan Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 02/10/2026).
The average price target is US$34.75, ranging from US$27.00 to US$40.00, with a median of US$36.00.
This is an external assessment, not a statement by Market Jury.
When does Cullinan Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 14% stronger than usual.
Does Cullinan Therapeutics pay a dividend?
No, Cullinan Therapeutics currently does not pay a dividend.
Which stocks are comparable to Cullinan Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cullinan Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cullinan Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.